ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to developing first-in-class therapeutics to protect and improve the vision of patients with retinal disease. By advancing a breakthrough technology designed to protect key retinal cells from Fas-mediated cell death, ONL is pioneering a new approach to preserving vision. ONL is developing a platform of products for use in a wide range of blinding diseases, including retinal detachment, glaucoma, AMD and IRD.
Location: United States, Michigan, Ann Arbor
Total raised: $93.8M
Investors 3
| Date | Name | Website |
| 17.03.2023 | Visionary ... | visionaryv... |
| - | Invest Mic... | investmich... |
| - | Grand Ange... | michiganca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.01.2022 | Series B | $46.9M | - |
| 24.12.2020 | Series B | $46.9M | - |
Mentions in press and media 13
| Date | Title | Description | Source |
| 08.03.2023 | ONL Therapeutics Closes First Tranche of $15 Million Series ... | - | globenewsw... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9M Series B Finan... | ONL Therapeutics, Inc.,, an Ann Arbor, Mich.-based clinical-stage biopharmaceutical company developi... | finsmes.co... |
| 13.01.2022 | Eye disease biotech raises $46.9M in Series B; Journey M... | ONL Therapeutics — an Ann Arbor, MI biotech that got its initial backing from Novartis in a ... | endpts.com... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series ... | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle gla... | globenewsw... |
| 13.01.2022 | ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series ... | – Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle gla... | marketscre... |
| 26.12.2020 | ONL Therapeutics secures US$ 46.9M in Series B funding | - | vcbay.news... |
| 24.12.2020 | ONL Therapeutics Raises $46.9M in Series B Financing | ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapi... | finsmes.co... |
| 22.12.2020 | Rolling on: ONL Therapeutics closes $46.9 million Series B f... | Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of g... | exsightven... |
| 22.12.2020 | ONL Therapeutics Closes $46.9 Million in Series B Financing ... | - | jnjinnovat... |
| 27.09.2018 | ONL Therapeutics is pioneering an entirely new approach to p... | ExSight is happy to announce an investment in ONL Therapeutics, Inc., an early stage biopharmaceutic... | exsightven... |
Show more